Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
A synthetic tetrapeptide (Ala-Glu-Asp-Gly) originally developed by the St. Petersburg Institute of Bioregulation and Gerontology in Russia. Studied for telomere lengthening, melatonin regulation, and anti-aging properties.
A coenzyme found in all living cells that plays a central role in energy metabolism and cellular repair. NAD+ levels decline significantly with age. Injectable NAD+ and its precursors (NMN, NR) have become widely used in longevity and anti-aging protocols.
Stimulates the pineal gland to increase melatonin production. Activates telomerase, an enzyme that maintains telomere length, potentially slowing cellular aging. Also reported to normalize circadian rhythms and modulate neuroendocrine function.
Serves as an electron carrier in cellular respiration (ATP production). Activates sirtuins (SIRT1-7), a family of proteins involved in DNA repair, inflammation regulation, and metabolic homeostasis. Also activates PARP enzymes involved in DNA damage repair.
- Anti-aging and longevity protocols
- Improved sleep quality
- Telomere length maintenance
- Cancer prevention (preliminary research)
- Circadian rhythm regulation
- Anti-aging and longevity protocols
- Energy and cognitive enhancement
- Addiction recovery support
- Athletic performance and recovery
- Metabolic health optimization
- Very limited human clinical data
- Most research from Russian institutions with limited peer review
- Long-term safety unknown
- Injection site reactions
- Theoretical concerns around telomerase activation and oncogenesis
- IV infusions can cause flushing, nausea, chest tightness (usually transient)
- Oral precursors (NMN, NR) generally well-tolerated
- Long-term effects of supraphysiological dosing unknown
- Theoretical concern: NAD+ may support cancer cell metabolism
- Quality varies significantly across suppliers
Removed from FDA 503A Category 2 effective April 22, 2026. Scheduled for PCAC review on July 24, 2026. Most research originates from Russian institutions; limited independent Western replication. Compounding not yet authorized — status is in regulatory gray zone pending PCAC recommendation.
PCAC: July 24, 2026
NAD+ itself is not FDA-approved as a drug. Injectable NAD+ is available through compounding pharmacies with a prescription. Oral precursors (NMN, NR) are sold as dietary supplements. Not on any FDA compounding category list — exists in a separate regulatory framework from the peptides affected by the 2026 reclassification.
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.